Discussion about this post

User's avatar
Elan Moritz's avatar

Fascinating analysis. Great points on lost opportunity, costs to public in terms of health, trust, and public funds. Cost to scientific community at large, as well as to individuals who serve on reviews, committees, research time... and lots more. Sad, but very really reflection of the nature of humans. More readily apparent in some areas than others. I would like to think that scientists are more immune to temptations of glory money and power, but the reality is they're not. The question is were to scientists rank in terms of basic malign character relative to other professions, such as politicians, clergy, bankers, investment 'advisers', real estate professionals, car dealers, ....

Expand full comment
ennui's avatar

Disclaimer: I am involved in commercial AD research.

Throat clear: fraud is bad and we should absolutely tar and feather (not to mention fire) the fraudsters.

I want to push back a little and say that I personally think the impact of these frauds on clinical development is overstated.

For example, I do not know of any drugs in development which specifically target Lesné's Aβ*56 species, and yet his fraud is used to cast doubt on the whole Aβ field, including the approved monoclonal therapies (which of course have very small effects and all that, and that's a justified critique, but they're certainly not based on the fraud).

Same for prasinezumab: with or without Masliah, there is still a rationale to at least try and target alpha synuclein.

Cassava is a joke company and a meme stock, they will keep promoting their failed molecule for as long as people give them money. This one is for the SEC to solve, not scientists.

I never saw the "string links" formulation of the problem but I must say I kind of like it as a theoretical framework, as long as we admit that poor quality research should be discouraged and fraud should be punished.

When I was in academia, in an entirely different field, we all knew not to trust the results of certain labs (or colleagues!) without in-house replication. Correcting the record is extremely difficult, as is knowing intent, and not everyone has the persistence to pursue it. I think in practice a lot of shoddy and fraudulent research is just ignored by those in the know, which is like, not great! For sure. But it's workable, and that's the strong links theory in practice.

On the other hand I'm increasingly worried about how this interacts with the training of various knowlege-extracting LLMs which are increasingly used by researchers and often cannot see beyond the context of an abstract.

Expand full comment
3 more comments...

No posts